InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc. is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets. CGuard EPS combines a self-expanding nitinol stent with an ultrathin polyethylene terephthalate (PET) MicroNet mesh, designed to trap plaque fragments and reduce the risk of peri-procedural stroke. Clinical data have demonstrated promising rates of procedural success and low incidence of embolic complications, positioning CGuard EPS as a leading choice for interventionalists in Europe, Latin America, and parts of Asia Pacific.

InspireMD was founded in 2002 and has since established a presence in key global markets outside the United States, while continuing to pursue regulatory clearance from the U.S. Food and Drug Administration. The company maintains headquarters in Tel Aviv, Israel, with additional offices in the United States to support clinical and regulatory activities. InspireMD collaborates with hospitals, research institutions, and distributors worldwide to broaden access to its stent systems and to advance the clinical evidence base for its technology.

The company is guided by a management team with seasoned expertise in interventional cardiology, neurology, regulatory affairs and medical device commercialization. InspireMD remains committed to innovation in vascular therapy and continues to invest in product development, clinical research and strategic partnerships to address unmet needs in the treatment of atherosclerotic and neurovascular diseases.

Key Stats

• Today's Range: $2.40 to $2.43
• 50-Day Range: $2.30 to $2.79
• 52-Week Range: $1.99 to $3.80
• Volume: 13,431 shs
• Average Volume: 98,719 shs
• Market Capitalization: $100.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 72% of companies evaluated by MarketBeat, and ranked 299th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

InspireMD has a consensus price target of $4.50, representing about 87.5% upside from its current price of $2.40.

Amount of Analyst Coverage

InspireMD has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.69% of the float of InspireMD has been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently decreased by 58.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.69% of the float of InspireMD has been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently decreased by 58.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.98

News Sentiment

InspireMD has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for InspireMD this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $249,996.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

34.06% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NSPR Stock Analysis - Frequently Asked Questions

How have NSPR shares performed this year?

InspireMD's stock was trading at $2.63 at the start of the year. Since then, NSPR shares have decreased by 8.7% and is now trading at $2.40.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%.

Who are InspireMD's major shareholders?

Top institutional investors of InspireMD include Rosalind Advisors Inc. (5.49%), Soleus Capital Management L.P. (4.52%), Huntleigh Advisors Inc. (0.41%) and Raymond James Financial Inc. (0.11%). Insiders that own company stock include Marvin Slosman, Gary S Roubin, Paul Stuka and Thomas J Kester.
View institutional ownership trends.

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NSPR
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InspireMD: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +87.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.92 million
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $7.07 million
• Price / Sales: 14.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 41,721,000
• Free Float: 18,332,000
• Market Cap: $100.13 million
• Optionable: Optionable
• Beta: 0.68